ANAntonio Coutinho Madruga Neto

Antonio Coutinho Madruga Neto

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Antonio Coutinho Madruga Neto has a total of 18 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Efficacy and Safety of Endoscopic Sleeve Gastroplasty at Mid Term in the Management of Overweight and Obese Patients: a Systematic Review and Meta-Analysis

    by Antonio Afonso de Miranda Neto, Diogo Turiani Hourneaux de Moura, Igor Braga Ribeiro, Ahmad Khan, Shailendra Singh, Alberto Machado da Ponte Neto, Antonio Coutinho Madruga Neto, Epifanio Silvino Do Monte Junior, Francisco Tustumi, Wanderley Marques Bernardo, et al.

    Background Endoscopic sleeve gastroplasty (ESG) has emerged as a promising technique in endoscopic bariatric and metabolic therapies (EBMTs). We aimed to perform a systematic review and meta-analysis to provide an update on its efficacy and safety. Methods This is a systematic review and meta-analysis was performed following the PRISMA guidelines. MEDLINE, Cochrane, EMBASE, and LILACS were searched to identify the studies related to ESG. Results Eleven studies with a total of 2170 patients were included. The average BMI pre-ESG was 35.78 kg/m2. Pooled mean %TWL observed at 6, 12, and 18 months was 15.3%, 16.1%, and 16.8% respectively. Pooled mean %EWL at 6, 12, and 18 months was 55.8%, 60%, and 73% respectively. No procedure-related mortality was reported. Conclusion ESG is a safe and effective procedure for primary obesity therapy with promising short- and mid-term results.


  • Stent migration requiring surgical removal: a serious adverse event after bariatric megastent placement

    by Antonio C. Madruga Neto, Vitor O. Brunaldi, Ossamu Okazaki, Marco A. Santo Filho, Vera L. Anapaz, Eduardo G. H. de Moura

    Leaks are serious complications after sleeve gastrectomy, with an incidence rate up to 7 % [1]. Currently, stent placement and other endoscopic techniques are recommended for the treatment of post-bariatric leaks (PBLs) [2]. Bariatric stents are a feasible, effective and life-saving method [3]. They achieve leak closure rates between 72.8 % and 87.8 % but are associated with significant migration rates (16.9 % – 28.2 %) [1] [4]. The large bariatric-specific stent (LBSS) has been developed as an important device to fit bariatric anatomy and avoid migration because of its long length with the distal edge being placed in the duodenum [5]. We report the case of 34-year-old woman who underwent sleeve gastrectomy. On the 5th post-operative day (POD), she developed abdominal pain and purulent output from the drain. Computed tomography (CT) scanning showed a leak at the angle of His without any collections. We opted to place an LBSS (24 cm × 28 mm; Hanarostent, MITECH) to bypass the whole stomach ([Fig. 1]). The LBSS was removed 4 weeks later (33th POD), but the leak persisted. We then placed two single-pigtail stents ([Fig. 2]) and kept them in place for 10 days, but this was also unsuccessful. On the 43 rd POD, we removed the pigtail stents, performed a septotomy, and placed a second LBSS ([Fig. 3]). After 3 weeks (64th POD), the patient again presented with abdominal pain. On this occasion, esophagogastroduodenoscopy (EGD) and upper gastrointestinal series showed complete closure of the leak, but the LBSS could not be seen. A CT scan identified the stent in the proximal jejunum ([Fig. 4]). An enteroscopic attempt to retrieve the stent and 7 days of conservative treatment (laxative, diet, and antispasmodic drug) were unsuccessful, and a laparoscopic enterectomy and primary anastomosis were eventually needed ([Fig. 5]). Finally, 15 days later (86th POD), she was asymptomatic and an EGD showed only a shallow ulcer at the angle of His ([Fig. 6]; [Video 1]). Video 1 Insertion of the first bariatric megastent to treat a leak; removal of the megastent and insertion of two single-pigtail stents; removal of pigtail stents and insertion of a second megastent; the bariatric megastent is found to have migrated into the small bowel and eventually required surgical removal. An LBSS seems to be a useful device for PBL management, but it may cause serious adverse events. Further controlled studies should assess the precise success and complication rates of such stent. Endoscopy_UCTN_Code_CPL_1AH_2AK


  • The Effectiveness of Endoscopic Gastroplasty for Obesity Treatment According to FDA Thresholds: Systematic Review and Meta-Analysis Based on Randomized Controlled Trials

    by Antonio Coutinho Madruga-Neto, Wanderley Marques Bernardo, Diogo Turiani Hourneaux de Moura, Vitor Ottoboni Brunaldi, Rafael Krieger Martins, Iatagan Rocha Josino, Thiago Ferreira de Souza, Marco Aurélio Santo, Eduardo Guimarães Hourneaux de Moura

    Endoscopic bariatric therapies (EBTs) are promising alternatives to conventional surgery for obesity. The aim of this study is to compare efficacy and safety through a systematic review and meta-analysis of the endoscopic gastroplasty techniques versus conservative treatment. We searched MEDLINE, EMBASE, Cochrane CENTRAL, Lilacs/Bireme. Randomized controlled trials (RCTs) enrolling obese patients comparing endoscopic gastroplasty to sham or diet/exercise were considered eligible. Among 6014 records, three RCTs were selected for meta-analysis. The total sample was 459 patients (312 EBTs vs 147 control). Mean total body weight loss in the intervention group (IG) was 4.8% higher than the control group (CG) at 12 months (p = 0.01). The IG responder rate was 44.31% at 12 months. Therefore, the endoscopic gastroplasty is more effective than conservative therapies but do not achieve FDA thresholds.